Skip to content

Korean Multicenter Prospective Registry of In.PACT DEB for Isolated Popliteal Artery Disease (K-POP Study)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02698345
Enrollment
100
Registered
2016-03-03
Start date
2016-01-31
Completion date
2021-03-31
Last updated
2019-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Popliteal Artery Disease

Keywords

Popliteal artery disease, drug-eluting balloon, angioplasty

Brief summary

* Prospective, multi-center, single-arm registry study * A total of 100 subjects with isolated popliteal artery lesions according to inclusion and exclusion criteria will be enrolled. * All popliteal artery lesions will be treated with drug-eluting balloon (In.PACT Admiral, Medtronic). • Atherectomy or use of bare nitinol stent in combination with drug-eluting balloon is allowed • Patients will be followed clinically for 12 months after the procedure. * Imaging study (Duplex ultrasound, CT angiography or catheter angiography) follow-up will be performed at 12 months.

Interventions

DEVICEdrug-eluting balloon (In.PACT Admiral, Medtronic)

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Age 19 years or older 2. Symptomatic peripheral artery disease: * Moderate or severe claudication (Rutherford category 2 or 3) * Critical limb ischemia (Rutherford category 4 or 5) 3. Atherosclerotic popliteal artery disease (stenosis \> 50%) 4. Patients with signed informed consent

Exclusion criteria

1. Acute critical limb ischemia 2. Severe critical limb ischemia (Rutherford category 6) 3. Involvement of SFA disease with stenosis 4. Continous total occlusion of all proximal infrapopliteal arteries (origin of the anterior tibial artery or tibioperoneal trunk). 5. Known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, or contrast agent 6. Age \> 85 years 7. Severe hepatic dysfunction (\> 3 times normal reference values) 8. Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis 9. LVEF \< 40% or clinically overt congestive heart failure 10. Pregnant women or women with potential childbearing 11. Life expectancy \<1 year due to comorbidity 12. Previous bypass surgery or stenting for the target popliteal artery 13. Untreated inflow disease of the ipsilateral pelvic or femoropopliteal arteries (more than 50% stenosis or occlusion)

Design outcomes

Primary

MeasureTime frameDescription
Primary patency rate12 months after the index procedureabsence of restenosis \>50% based on an imaging study (Duplex ultrasound, CT angiography or catheter angiography) at 12 months

Secondary

MeasureTime frameDescription
Target vessel revascularization rate12 monthsfrequency of repeat intervention or surgical treatment due to loss of patency at the target vessel

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026